BioLargo, Inc. (BLGO)
OTCMKTS · Delayed Price · Currency is USD
0.1040
+0.0025 (2.46%)
At close: Aug 14, 2026
BioLargo Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.12 | 3.88 | 3.55 | 3.54 | 1.85 | 0.96 |
Cash & Short-Term Investments | 4.12 | 3.88 | 3.55 | 3.54 | 1.85 | 0.96 |
Cash Growth | 60.76% | 9.44% | 0.25% | 91.19% | 92.41% | 34.36% |
Receivables | 0.73 | 0.62 | 3.17 | 2.61 | 1.06 | 0.51 |
Inventory | 0.29 | 0.31 | 0.33 | 0.15 | 0.12 | 0.24 |
Prepaid Expenses | 0.3 | 0.31 | 0.09 | 0.06 | 0.12 | 0.09 |
Total Current Assets | 5.45 | 5.11 | 7.14 | 6.36 | 3.15 | 1.8 |
Property, Plant & Equipment | 2.93 | 3.01 | 3.19 | 1.75 | 1.15 | 0.51 |
Long-Term Investments | - | - | 0.01 | 0.02 | 0.03 | 0.05 |
Other Intangible Assets | 0.03 | - | - | - | - | - |
Other Long-Term Assets | 0.07 | 0.11 | 0.1 | 0.07 | 0.52 | 0.66 |
Total Assets | 8.57 | 8.31 | 10.51 | 8.21 | 4.86 | 3.02 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.29 | 1.65 | 1.07 | 1.35 | 0.9 | 0.5 |
Accrued Expenses | 0.27 | 0.22 | 0.15 | 0.3 | 0.28 | 0.29 |
Current Portion of Long-Term Debt | 1.51 | 1.48 | 0.55 | 0.3 | 0.1 | 0.31 |
Current Portion of Leases | 0.33 | 0.31 | 0.19 | 0.11 | 0.1 | 0.1 |
Current Unearned Revenue | 0.32 | 0.28 | - | 0.3 | 0.02 | 0.09 |
Other Current Liabilities | 1.21 | 1.13 | 0.68 | 0.36 | 0.18 | 0.08 |
Total Current Liabilities | 4.93 | 5.06 | 2.65 | 2.71 | 1.58 | 1.37 |
Long-Term Debt | 2.78 | 0.6 | 0.53 | 0.29 | 0.5 | 0.37 |
Long-Term Leases | 1.04 | 1.12 | 1.28 | 1 | 0.77 | 0.35 |
Total Liabilities | 8.75 | 6.79 | 4.46 | 4 | 2.85 | 2.09 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.21 | 0.21 | 0.2 | 0.2 | 0.19 | 0.17 |
Additional Paid-In Capital | 165.35 | 165.32 | 158.33 | 154.02 | 148.44 | 143.72 |
Retained Earnings | -163.57 | -161.28 | -149.5 | -147.1 | -143.59 | -139.12 |
Comprehensive Income & Other | -0.21 | -0.21 | -0.18 | -0.28 | -0.15 | -0.12 |
Total Common Equity | 1.79 | 4.04 | 8.85 | 6.84 | 4.88 | 4.65 |
Minority Interest | -1.97 | -2.52 | -2.8 | -2.64 | -2.87 | -3.72 |
Shareholders' Equity | -0.19 | 1.53 | 6.06 | 4.2 | 2.01 | 0.93 |
Total Liabilities & Equity | 8.57 | 8.31 | 10.51 | 8.21 | 4.86 | 3.02 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 5.66 | 3.51 | 2.55 | 1.7 | 1.47 | 1.13 |
Net Cash (Debt) | -1.54 | 0.37 | 0.99 | 1.84 | 0.38 | -0.17 |
Net Cash Growth | - | -62.78% | -46.01% | 380.68% | - | - |
Net Cash Per Share | -0.00 | 0.00 | 0.00 | 0.01 | 0.00 | -0.00 |
Filing Date Shares Outstanding | 320.88 | 319.75 | 301.3 | 295.55 | 283.19 | 262.72 |
Total Common Shares Outstanding | 319.7 | 317.38 | 301.27 | 292.95 | 278.46 | 255.89 |
Working Capital | 0.51 | 0.05 | 4.49 | 3.65 | 1.58 | 0.43 |
Book Value Per Share | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | 0.02 |
Tangible Book Value | 1.75 | 4.04 | 8.85 | 6.84 | 4.88 | 4.65 |
Tangible Book Value Per Share | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | 0.02 |